The Conversation (0)
May 05, 2025
Alert Options
No alert set
INN Article Notification
Alert Option
You will be notified when this event occurs. No additional settings needed.
29 August 2025
FY25 Preliminary Results Summary and Company Update
Cardiex Limited (CDX:AU) has announced FY25 Preliminary Results Summary and Company UpdateDownload the PDF here. Keep Reading...
29 August 2025
Appendix 4E
Cardiex Limited (CDX:AU) has announced Appendix 4EDownload the PDF here. Keep Reading...
31 July 2025
June Quarterly Appendix 4C
Cardiex Limited (CDX:AU) has announced June Quarterly Appendix 4CDownload the PDF here. Keep Reading...
31 July 2025
June Quarterly Activities Report
Cardiex Limited (CDX:AU) has announced June Quarterly Activities ReportDownload the PDF here. Keep Reading...
24 June 2025
Results of Entitlement Offer
Cardiex Limited (CDX:AU) has announced Results of Entitlement OfferDownload the PDF here. Keep Reading...
09 September
Lexaria Announces Closing of Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds
KELOWNA, BC / ACCESS Newswire / September 9, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today closed its previously announced exercise of certain outstanding warrants to purchase an aggregate of 453,969 shares of the... Keep Reading...
08 September
Lexaria Announces Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds
KELOWNA, BC / ACCESS Newswire / September 8, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to... Keep Reading...
04 September
Lexaria to Present at the H.C. Wainwright 28th Annual Global Investment Conference
KELOWNA, BC / ACCESS Newswire / September 4, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, announces that it will participate in the 28th Annual H.C. Wainwright Global Investment Conference, taking place September... Keep Reading...
01 September
BriaCell's Cell-Based ‘Melanoma’ Enters the Skin Cancer Vaccine Conversation
Clinical-stage immuno-oncology company BriaCell Therapeutics (TSX:BCT,NASDAQ:BCTX) has achieved a “key genetic engineering milestone” with ‘Melanoma’, its personalized whole-cell melanoma immunotherapy vaccine candidate.The achievement allows the vaccine’s program to proceed towards clinical... Keep Reading...
01 September
Lexaria Receives USD$2.6 Million Tax Rebate Payment
Lexaria's 2025 Australian human study results in a USD$2.6 million cash rebate KELOWNA, BC / ACCESS Newswire / September 1, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, is pleased to announce that it has received... Keep Reading...
24 August
DehydraTECH-enhanced Amycretin and Retatrutide Yield Significant Absorption Improvements in Lexaria's 2026 Animal Study #2
Proprietary DehydraTECH 3.0 amycretin tablet formulation more than doubled absolute bioavailability compared to a leading industry study Proprietary DehydraTECH 3.0 retatrutide tablet formulation increased drug absorption by as much as an astonishing 4,552% compared to the DehydraTECH 2.0... Keep Reading...
Latest News
Interactive Chart
Latest Press Releases
Related News
TOP STOCKS
American Battery4.030.24
Aion Therapeutic0.10-0.01
Cybin Corp2.140.00